Literature DB >> 28968189

Impacts of the Human Gut Microbiome on Therapeutics.

Yoshiki Vázquez-Baeza1, Chris Callewaert2, Justine Debelius2, Embriette Hyde2, Clarisse Marotz3, James T Morton1, Austin Swafford4, Alison Vrbanac3, Pieter C Dorrestein5, Rob Knight1,2,4.   

Abstract

The human microbiome contains a vast source of genetic and biochemical variation, and its impacts on therapeutic responses are just beginning to be understood. This expanded understanding is especially important because the human microbiome differs far more among different people than does the human genome, and it is also dramatically easier to change. Here, we describe some of the major factors driving differences in the human microbiome among individuals and populations. We then describe some of the many ways in which gut microbes modify the action of specific chemotherapeutic agents, including nonsteroidal anti-inflammatory drugs and cardiac glycosides, and outline the potential of fecal microbiota transplant as a therapeutic. Intriguingly, microbes also alter how hosts respond to therapeutic agents through various pathways acting at distal sites. Finally, we discuss some of the computational and practical issues surrounding use of the microbiome to stratify individuals for drug response, and we envision a future where the microbiome will be modified to increase everyone's potential to benefit from therapy.

Entities:  

Keywords:  metabolome; microbial ecology; microbiome; personalized medicine; precision medicine

Mesh:

Substances:

Year:  2017        PMID: 28968189     DOI: 10.1146/annurev-pharmtox-042017-031849

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  25 in total

1.  A phylogenetic model for the recruitment of species into microbial communities and application to studies of the human microbiome.

Authors:  John L Darcy; Alex D Washburne; Michael S Robeson; Tiffany Prest; Steven K Schmidt; Catherine A Lozupone
Journal:  ISME J       Date:  2020-02-19       Impact factor: 10.302

2.  Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking.

Authors:  Kieng B Vang; Ruud P M Dings; Samir V Jenkins; Michael S Robeson; Robert J Griffin; Charles M Quick; Eric R Siegel; Martin J Cannon
Journal:  Cancer Res       Date:  2019-10-07       Impact factor: 12.701

Review 3.  Precision medicine journey through omics approach.

Authors:  Mandana Hasanzad; Negar Sarhangi; Sima Ehsani Chimeh; Nayereh Ayati; Monireh Afzali; Fatemeh Khatami; Shekoufeh Nikfar; Hamid Reza Aghaei Meybodi
Journal:  J Diabetes Metab Disord       Date:  2021-11-24

4.  Dietary Supplementation of Chitosan Oligosaccharide-Clostridium butyricum Synbiotic Relieved Early-Weaned Stress by Improving Intestinal Health on Pigeon Squabs (Columba livia).

Authors:  Jiashu Wen; Wenyan Zhao; Jiankui Li; Caihong Hu; Xiaoting Zou; Xinyang Dong
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 5.  Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure.

Authors:  Jonel Trebicka; Thomas Reiberger; Wim Laleman
Journal:  Visc Med       Date:  2018-07-13

6.  What will it take to understand the ecology of symbiotic microorganisms?

Authors:  Angela E Douglas
Journal:  Environ Microbiol       Date:  2018-05-11       Impact factor: 5.491

7.  Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases.

Authors:  Ibrahim Choucair; Ina Nemet; Lin Li; Margaret A Cole; Sarah M Skye; Jennifer D Kirsop; Michael A Fischbach; Valentin Gogonea; J Mark Brown; W H Wilson Tang; Stanley L Hazen
Journal:  J Lipid Res       Date:  2019-12-09       Impact factor: 5.922

Review 8.  Multi-omics data integration considerations and study design for biological systems and disease.

Authors:  Stefan Graw; Kevin Chappell; Charity L Washam; Allen Gies; Jordan Bird; Michael S Robeson; Stephanie D Byrum
Journal:  Mol Omics       Date:  2021-04-19

Review 9.  The gut microbiota can be a potential regulator and treatment target of bone metastasis.

Authors:  Kelly F Contino; Hariom Yadav; Yusuke Shiozawa
Journal:  Biochem Pharmacol       Date:  2022-01-15       Impact factor: 5.858

Review 10.  The microbiome and prostate cancer.

Authors:  Juan Javier-DesLoges; Rana R McKay; Austin D Swafford; Gregory D Sepich-Poore; Rob Knight; J Kellogg Parsons
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-07-15       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.